LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. “We are delighted to welcome Minako to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer. “Dr. Pazdera has broad expertise encompassing both financial and strategic transactions, as well a deep understanding of intellectual property law and corporate compliance. Her contributions will be invaluable as we advance the development of LB-102 and work towards our broader vision of building a fully integrated CNS-focused company.” Before joining LB Pharmaceutic
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)GlobeNewswire
- LB Pharmaceuticals (LBRX) had its price target raised by Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- LB Pharmaceuticals Inc GAAP EPS of -$0.45 [Seeking Alpha]Seeking Alpha
- LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with SchizophreniaGlobeNewswire
LBRX
Earnings
- 3/26/26 - In-Line
LBRX
Sec Filings
- 3/26/26 - Form S-8
- 3/26/26 - Form 10-K
- 3/26/26 - Form 8-K
- LBRX's page on the SEC website